474432-59-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Pyrazolo[1,5-a]pyridine-5-carboxaldehyde (9CI) is used as a key intermediate in the synthesis of pharmaceuticals for its ability to react with various functional groups, contributing to the development of new drugs with potential therapeutic applications.
Used in Organic Chemistry Research:
In the field of organic chemistry, Pyrazolo[1,5-a]pyridine-5-carboxaldehyde (9CI) is utilized as a versatile building block for the creation of complex organic molecules, facilitating the exploration of novel chemical reactions and the discovery of new compounds with unique properties.
Used in Drug Discovery:
Pyrazolo[1,5-a]pyridine-5-carboxaldehyde (9CI) is employed as a starting material in drug discovery processes, where its reactivity and structural features are leveraged to design and synthesize new molecular entities with potential medicinal value.
Used in Medicinal Chemistry:
In medicinal chemistry, Pyrazolo[1,5-a]pyridine-5-carboxaldehyde (9CI) is used as a scaffold for the development of bioactive molecules, with its pyrazolo-pyridine core offering a promising template for the attachment of various pharmacophores to enhance drug-target interactions and improve therapeutic efficacy.
Used in Chemical Compound Libraries:
Pyrazolo[1,5-a]pyridine-5-carboxaldehyde (9CI) is incorporated into chemical compound libraries for high-throughput screening in drug discovery, providing a diverse set of structurally related compounds for the identification of lead candidates with potential biological activity.

Upstream product

• 474432-57-0 5-hydroxymethylpyrazolo[1,5-a]pyridine 
• 1260770-97-5 ethyl 5-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate 
• 104468-87-3 pyrazolo [1,5-a]pyridine-5-carboxylic acid 
• 586-95-8 pyridine-4-methanol 
• 474432-56-9 methyl 5-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate 

Downstream Products

• 104468-87-3 pyrazolo [1,5-a]pyridine-5-carboxylic acid 

Relevant academic research and scientific papers

FUSED RING HETEROARYL COMPOUNDS AS ALK4/5 INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of ALK5 and/or ALK4 and are useful in the treatment of pulmonary fibrosis, NASH, obesity, diabetes, cancers and other inflammation.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Interactive SAR studies: Rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists

Starting from dopamine receptor ligand BP897, an interactive drug discovery process leading to heterocyclic bioisosteres is demonstrated. The four step strategy involved a careful optimization of geometric and electronic properties by systematic modificat